Vaccines |
(except for - those which are part of a routine immunization program in most/all provinces and territories: Diphtheria toxoid, Tetanus toxoid, Pertussis, Poliomyelitis, Haemophilus influenza type B, Measles, Mumps, Pneumococcus, Rubella, Hepatitis B Pediatric, Influenza, cholera vaccine (oral, inactivated) when used for prophylaxis against traveller's diarrhea & due to enterotoxigenic escherichia coli (ETEC); and those requiring special enhanced public access due to disease outbreaks: Meningococcus) |
I |
FEB / 02 |
Vaccines. |
which are part of a routine immunization program in most/all provinces and territories: Diptheria toxoid, Tetanus toxoid, Pertussis, Poliomyelitis, Haemophilus influenza type B, Measles, Mumps, Pneumococcus, Rubella, Hepatitis B Pediatric, Influenza, cholera vaccine (oral, inactivated) when used for prophylaxis against traveller's diarrhea & due to enterotoxigenic escherichia coli (ETEC); and those requiring special enhanced public access due to disease outbreaks: Meningococcus |
II |
FEB / 02 |
Valaciclovir or its saltsPDL |
|
I |
DEC / 13 |
Valdecoxib or its saltsPDL |
|
I |
DEC / 13 |
Valganciclovir or its salts or derivativesPDL |
|
I |
DEC / 13 |
Valproic acid or its saltsPDL |
Including but not limited to Divalproex sodium
|
I |
DEC / 13 |
Valrubicin or its derivativesPDL |
|
I |
DEC / 13 |
Valsartan or its salts or derivativesPDL |
|
I |
DEC / 13 |
Vancomycin or its salts or derivativesPDL |
Including but not limited to Telavancin.
|
I |
DEC / 13 |
Vandetanib or its salts or derivativesPDL |
|
I |
DEC / 13 |
Vardenafil or its saltsPDL |
|
I |
DEC / 13 |
Varenicline or its saltsPDL |
|
I |
DEC / 13 |
Varicella Zoster immune globulin |
|
I |
FEB / 02 |
Varicella vaccine (chicken pox) |
|
I |
FEB / 02 |
Vasopressin or its saltsPDL |
|
I |
DEC / 13 |
Vecuronium bromidePDL |
|
I |
DEC / 13 |
Vedaprofen or its salts or derivativesPDL |
|
I |
DEC / 13 |
VedolizumabPDL |
|
I |
MAR / 15 |
Vegetable tar |
except shampoos in concentrations of 5% or less |
III |
SEP / 98 |
Velaglucerase alfaPDL |
|
I |
DEC / 13 |
VelpatasvirPDL |
|
I |
AUG / 16 |
Vemurafenib or its salts or derivativesPDL |
|
I |
DEC / 13 |
Venetoclax or its saltsPDL |
|
I |
NOV / 16 |
Venlafaxine or its saltsPDL |
|
I |
DEC / 13 |
Verapamil or its saltsPDL |
|
I |
DEC / 13 |
Veratrum album or its alkaloids or their saltsPDL |
For human use.
|
I |
DEC / 13 |
Veratrum viride or its alkaloids or their saltsPDL |
For human use
|
I |
DEC / 13 |
Vernakalant or its saltsPDL |
|
I |
APR / 17 |
Verteporfin or its salts or derivatives PDL |
|
I |
DEC / 13 |
VidarabinePDL |
|
I |
DEC / 13 |
Vigabatrin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Vilanterol or its saltsPDL |
Including but not limited to Vilanterol trifenatate
|
I |
DEC / 13 |
Vilazodone or its saltsPDL |
|
I |
AUG / 15 |
Vinblastine or its saltsPDL |
|
I |
DEC / 13 |
Vincristine or its saltsPDL |
|
I |
DEC / 13 |
Vindesine or its saltsPDL |
|
I |
DEC / 13 |
Vinorelbine or its saltsPDL |
|
I |
DEC / 13 |
Viomycin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Virginiamycin or its salts or derivativesPDL |
|
I |
DEC / 18 |
VismodegibPDL |
|
I |
DEC / 13 |
Vitamin APDL |
For human use - in oral dosage forms containing more than 10,000 International Units of Vitamin A per dosage form or, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by that person of more than 10,000 International Units of Vitamin A.
|
I |
DEC / 13 |
Vitamin B12 with Intrinsic Factor ConcentratePDL |
|
I |
DEC / 13 |
Vitamin DPDL |
For human use - in oral dosage form containing more than 62.5 mcg or 2,500 International Units of Vitamin D per dosage form, or where the largest recommended daily dosage shown on the label would result in the daily intake by that person of more than 62.5 mcg or 2,500 International Units of Vitamin D
|
I |
FEB / 21 |
Vitamin KPDL |
For human use - except Vitamin K1 or Vitamin K2 sold (a) for external use in humans; or (b) in an oral dosage form for use in humans if the maximum recommended daily dose is 0.120 mg or less.
|
I |
DEC / 13 |
Vitamins |
any parenterals not otherwise included in Schedule I |
II |
SEP / 98 |
Vitamins in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Vorapaxar or its saltsPDL |
|
I |
AUG / 16 |
Voretigene neparvovecPDL |
|
I |
DEC / 20 |
VoriconazolePDL |
|
I |
DEC / 13 |
VorinostatPDL |
|
I |
DEC / 13 |
Vortioxetine or its saltsPDL |
including but not limited to vortioxetine hydrobromide
|
I |
DEC / 14 |
Voxilaprevir or its saltsPDL |
|
I |
SEP / 17 |